Subscribe to our Newsletters !!
Drug quality is defined not only how a drug is man
Eppendorf is launching the new VisioNize® box 2,
The journey and merging of sperm and egg cells is
This year, the Hamburg based life sciences company
Alembic Pharmaceutica
Since it’s an ingredient in so many foods, you h
In a world constantly in motion, Microbioz India r
Mumbai, 21st October 2020: BDR Pharmaceutical today announces the launch of 4mg and 10 mg of Lenvatinib under the brand name BDFOIE for the treatment of differentiated thyroid cancer, advanced liver cancer and advanced kidney cancer. Lenvatinib is priced at INR 1620 (4 mg) and INR 2970 (10 mg) for a pack of 10 capsules. Lenvatinib is a molecule used to provide breakthrough therapy treatment for cancer patients. The results of clinical trials conducted showed encouraging results with safety and efficacy on patients treated with aggressive tumors.
Mr.Dharmesh Shah, CMD, BDR Pharmaceuticals said, “2020 so far has been extraordinary on an operational front. By launching cost-effective therapy options we want to mitigate the challenges faced by Indian patients in seeking access to treatment and finding a timely cure for life threatening diseases. The launch of Lenvatinib is a step forward in providing breakthrough treatment options at an affordable price, reducing the average cost of treatment drastically”
About BDR Pharmaceuticals: BDR is recognized as a “niche” player in manufacturing of Pharmaceutical APIs and for the renowned new age formulations. BDR Group of companies has grown steadily in the pharmaceutical Industry over the last 15 years, in both domestic and international arenas. The group is complemented majorly by its two companies – BDR Pharmaceuticals International Pvt Ltd and BDR Life sciences Pvt. Ltd, each one having stamped its own supremacy in respective fields, i.e. API and formulation manufacturing, respectively. BDR Group focuses on development in 6 specialized therapeutic segments, viz. Oncology, Critical care, Gynecology & Neurology, Dermatology and Women’s Health which are its dream segment.
